Vitamin D in Health and Disease
Authors: Geoffrey M. Marel, Boy Frame, Anthony W. Norman
Journal: Annals of Internal Medicine (1982)

Symposium1 May 1982Vitamin D in Health and DiseaseGEOFFREY M. MAREL, M.B., B.S., BOY FRAME, M.D., ANTHONY W. NORMAN, PH.D.GEOFFREY M. MAREL, M.B., B.S.Search for more papers by this author, BOY FRAME, M.D.Search for more papers by this author, ANTHONY W. NORMAN, PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-5-674 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe burgeoning interest and expertise among both basic scientists and clinicians in the field of vitamin D metabolism, its endocrine system, and related diseases were evident at the Fifth Workshop on Vitaman D, held 14-19 February 1982, in Williamsburg, Virginia, and attended by over 450 delegates from 24 countries.It is now accepted that circulating vitamin D, as dietary ergocalciferol (D2) or cutaneously photosynthesized cholecalciferol (D3), is hydroxylated in successive steps in the liver and kidney (25- and 1α-hydroxylation, respectively) to its more potent metabolites, 25 hydroxy vitamin D (25(OH)D) and 1,25 dihydroxyvitamin D (1,25(OH)2D), before it exerts its physiologic...Symposium Papers1. OHNUMANORMAN NA. Discovery, isolation and chemical characterization of two new metabolites of vitamin D3: evidence for the existence of a new C-23 oxidation pathway for 1,25(OH)2D3. University of California; Riverside, California. Google Scholar2. SUDA T. The mechanism of differentiation of human myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. School of Dentistry, Showa University; Tokyo, Japan. Google Scholar3. EISMAN J. 1,25(OH)2D3 receptors in human cancer cells in culture. University of Melbourne, and Repatriation General Hospital; Melbourne, Victoria, Australia. Google Scholar4. LIBERMANEILMARX UCS. Receptor defects in cultured fibroblasts of patients with end-organ resistance to 1,25(OH)2D. National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, and National Naval Medical Center; Bethesda, Maryland. Google Scholar5. MANOLAGASHOWARDABARECULLERBRICKMANDEFTOS SJJFAL. Cytoreceptor assay for 1,25(OH)2D3: A convenient method and its application to clinical studies. University of California, San Diego; San Diego Veterans Administration Medical Center, La Jolla; UCLA School of Medicine, Los Angeles; and Sepulveda Veterans Administration Medical Center, Sepulveda, California. Google Scholar6. FRAHERJONESO'RIORDAN LGJ. Rapid preparation and evaluation of vitamin D metabolites for 25(OH)D and 1,25DHCC assays. Henry Ford Hospital; Detroit, Michigan. Google Scholar7. MATHEWSKLEEREKOPERPARFITT MMA. "Sep-pak" separation of vitamin D metabolites for 25(OH)D and 1,25DHCC assays. Henry Ford Hospital; Detroit, Michigan. Google Scholar8. FRAHERBAKERO'RIORDAN LTJ. Development of a solid phase radioimmunoassay for 1,25DHCC. Middlesex Hospital; London, England. Google Scholar9. HENDERSONCLEMENSHANNAFINHOLICKBAGGIOLINIUSKOKOVIC STNMEM. Development of a sensitive and specific assay for 1,25(OH)2D3 using antibodies raised against 1-OH-cholecalcioic acid-bovine serum albumin. Massachusetts General Hospital, Boston, Massachusetts; and Hoffman-LaRoche, Nutley, New Jersey. Google Scholar10. JONGENVANVIJGHLIPSNETELENBOS MDWPJ. 1,25(OH)2D3 measurements in anephric subjects. Free University Hospital; Amsterdam, The Netherlands. Google Scholar11. MAWER E. Regulation of 1,25(OH)2D in health and disease. University of Manchester Medical School; Manchester, England. Google Scholar12. GRAYMCADOOWILLIAMSTHIERRY-PALMERLESTERHATLEY TTMMGL. Circulating levels of 1,25(OH)2D3 vary during the menstrual cycle. University of North Carolina School of Medicine; Chapel Hill, North Carolina. Google Scholar13. LEMANNADAMSGRAY JNR. Liquid formula diets reduce serum 1,25(OH)2 vit. D concentrations in humans. Medical College of Wisconsin; Milwaukee, Wisconsin. Google Scholar14. BROWNHAMDAWBORNXIPELL DKJJ. D-resistant osteomalacia in dialysis patients: bone collagen and mineral content and treatment with desferrioxamine and calcitriol. Austin Hospital; Heidelberg, Victoria, Australia. Google Scholar15. SHERRARDOTTMALONEYCOBURN DSNJ. Use of 24,25(OH)2D in renal osteodystrophy. Seattle Veterans Administration Medical Center and University of Washington, Seattle, Washington; Los Angeles Veterans Administration Medical Center and UCLA School of Medicine, Los Angeles, California. Google Scholar16. EVANSHILLSWONGDUNSTANNORMAN RESCA. The use of 24,25DHCC alone and in combination with 1,25DHCC in C. R.F. Concord Hospital, New South Wales, Australia; and University of California, Riverside, California. Google Scholar17. OLGAARDROTHSTEINARBELAEZSLATAPOLSKY KMME. Does 24,25 (OH)2D3 have a beneficial effect in uremia? Washington University School of Medicine; St. Louis, Missouri. Google Scholar18. COBURNSHERRARDOTTHODSMANDIDOMENICOALFREY JDSANA. Bone disease in uremia: a reappraisal. Veterans Administration, Wadsworth Medical Center and UCLA School of Medicine, Los Angeles, California; Veterans Administration Medical Center and University of Washington, Seattle, Washington; and Veterans Administration Medical Center, University of Colorado, Denver, Colorado. Google Scholar19. FELETTIDOCCIDIFELICECOLIBONOMINI CDALV. Is 1,25DHCC "effective" in the treatment of uremic osteodystrophy? S. Orsola University Hospital; Bologna, Italy. Google Scholar20. KUMAR R. Evaluation of the enterohepatic circulation and metabolism of vitamin D. Mayo Clinic and Foundation; Rochester, Minnesota. Google Scholar21. RASMUSSENGERTNERINSOGNA HJK. Treatment of familial hypophosphatemic rickets with 1α(OH)D3 and 1,25(OH)2D3. Yale University; New Haven, Connecticut. Google Scholar22. DREZNERLYLESWHITESIDESHARRELSON MKPJ. 1,25(OH)2D3 and phosphate therapy in X-linked hypophosphatemic rickets completely heals the bone disease. Duke University Medical Center; Durham, North Carolina. Google Scholar23. DREZNER M. Clinical experience with 1,25(OH)2D3: oncogenic osteomalacia. Duke University Medical Center; Durham, North Carolina. Google Scholar24. MILLERMARELFRAMENEER MGBR. Adult acquired vitamin D and parathyroid hormone resistant hypophosphatemic osteomalacia with multiple skeletal lesions. Midland Hospital Center, Midland, Michigan; Henry Ford Hospital, Detroit, Michigan; and Massachusetts General Hosptal, Boston, Massachusetts. Google Scholar25. RIGGS B. Vitamin D metabolism in involutional osteoporosis: evidence for etiologic heterogeneity. Mayo Clinic and Foundation; Rochester, Minnesota. Google Scholar26. NEERSLOVIKADAMSHOLICK RDJM. Deficient 1,25(OH)2D production in elderly osteoporotic patients. Massachusetts General Hospital; Boston, Massachusetts. Google Scholar27. MATHEWSMATKOVICWALCZAKPARFITT MVNA. Bone mineral density and 25-hydroxy-D measurements in elderly nursing home residents. Henry Ford Hospital; Detroit, Michigan. Google Scholar28. CHRISTIANSEN C. Osteoporosis and vitamin D metabolites: a status report. Glostrup Hospital; Denmark. Google Scholar29. CANIGGIANUTI AR. 25(OH)Vitamin D counteracts the impairment of intestinal calcium transport in patients on long-term treatment with glucoactive corticosteroids. Clinica Medica, University of Siena; Siena, Italy. Google Scholar30. SANDLERCLEMENSO'RIORDAN LTJ. The pharmacokinetics of 1,25DHCC. Middlesex Hospital; London, England. Google Scholar31. HOLICK M. The photobiology of vitamin D3. Massachusetts General Hospital; Boston, Massachusetts. Google Scholar32. HOLLISJACOBSALLMANROTHBOURGOIGNIELAMBERT BAADJP. Uremia causes a retardation in the photoproduction of vitamin D. Case Western Reserve University School of Medicine, Cleveland, Ohio; and University of Miami School of Medicine, Miami, Florida. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Division of Bone and Mineral Metabolism Henry Ford Hospital Detroit, MichiganDepartment of Biochemistry University of California Riverside, California PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byChemical AbnormalitiesCalcium, Vitamin D and Parathyroid Hormone. Related Aspects in the Neonatal Period 1 May 1982Volume 96, Issue 5Page: 674-677KeywordsEndocrine systemLiverMetabolitesRenal circulationScientistsVitamin D Issue Published: 1 May 1982 PDF downloadLoading ...